|
Monday, April 14, 2008
Embassy Suites, Chesterbrook, Pennsylvania (directions)
|
Transave
A private biopharmaceutical company
About
|
TRANSAVE is a private biopharmaceutical company with a mission to improve the treatment of serious lung diseases through the company's next generation liposomal delivery technology providing prolonged release of a drug in the lung while minimizing systemic exposure, which may improve the therapeutic index in the treatment of lung infections that have a pseudomonas component, such as cystic fibrosis and bronchiectasis, and enable non-toxic pulmonary delivery of siRNA molecules.
Their lead compound is Arikace™ a liposomal formulation of amikacin that is delivered through the pulmonary route via nebulization to cystic fibrosis patients to treat Pseudomonas aeruginosa infections. Arikace™ is currently enrolling two Phase 2b studies one each in Europe and the US. Results from the European study are expected during the second quarter of 2008 and the US results by year end. Investors are interested in either exiting or partnering Arikace prior to initiating Phase 3.
Transave also has a unique delivery technology for Liposomal Delivery of siRNAs. Gene silencing mediated by small intracellular RNAs is a recently discovered phenomenon with potentially large impact in functional genomics, target discovery/validation and biopharmaceutics. Significant investments are being made by both Biotech (Alnylam, Silence, ISIS) and big pharma (Merck, Novartis, GSK, AstraZeneca) companies. The approach suffers from major obstacles related to the delivery of these molecules to the site of action. Transave's approach may offer significant advantages for both pulmonary and systemic delivery of oligonucleotides via a safer non-cationic liposomal delivery system for RNAi. Technical proof of concept experiments are being conducted at the company with results expected during April.
3 Major Issues
|
- Is it better to position Transave as a platform/delivery company or spin out the siRNA delivery technology to maximize value prior to an M&A exit?
- How much value can be generated in a partnering deal or M&A exit for second/additional indications such as Bronchiectasis or non-TB Micobacterium in addition to our primary indication in cystic fibrosis?
- What are the trade offs of doing exclusive vs. non-exclusive deals for delivery technologies such as our Liposomal siRNA delivery system?
Program:
|
6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)
8:00 - Nick Gurreri, Sr. VP Comm. Ops & Bus. Dev., will deliver the Company's
"Elevator" Pitch to the Group
8:15 - A Panel will address 3 Major Issues for the Company
9:00 - Open discussion: members and guests
<Top of the page>
|
 |
|
 Slides
None available at this time
 Audio
None available at this time
 Video
None available at this time
 Webcast
None available at this time
|
|
|
